Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

NCT00049127 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Adult Anaplastic Oligodendroglioma
Adult Mixed Glioma
Adult Oligodendroglioma
Recurrent Adult Brain Neoplasm

Interventions

DRUG: Imatinib Mesylate
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]